[Clinical Chemistry and Laboratory Medicine (CCLM)] Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group.pdf
[en] Background Previous studies have suggested that exercising may induce cardiac damage. Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis. We aimed to compare the kinetics of emerging fibrosis cardiac biomarkers as Gal-3 and ST-2 in endurance runners, and recreational runners before and after a running event represented by a marathon and an ultratrail event. Methods Blood samples were taken from 19 healthy non-elite marathon runners (42 km), 27 ultratour runners (67 km), and 14 recreational runners who represented the control group (10 km) just before the run (T0), just after (T1) and 3 h after (T2), in order to analyze Gal-3, ST2, hsTnT, NT-proBNP, CKMB and hsCRP. We compared the percentage of evolution and the slopes obtained from T0 to T1 (pT0T1) and from T1 to T2 (pT1T2), between the different groups of runners participating in three different races. Results Plasma cardiac biomarker concentrations increased significantly from baseline to immediately post-exercise and most of the time decreased over the subsequent 3-h period. For pT0T1 and pT1T2, the markers Gal-3 and ST2 showed a significant difference between types of run (p < 0.05 and p < 0.0001, respectively). During the recovery time, Gal-3 returned to the baseline values but not ST2 which continued to increase. Conclusions Gal-3 and ST2 are considered as a reflection of cardiac fibrosis and remodeling. The evolution of both was different, particularly after the recovery time. ST2 values exceeding cutoff values at any time.
Disciplines :
Orthopedics, rehabilitation & sports medicine Laboratory medicine & medical technology
Author, co-author :
LE GOFF, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire techniques séparatives et stress oxydant
Kaux, Jean-François ; Université de Liège - ULiège > Département des sciences de la motricité > Département des sciences de la motricité
Farre Segura, Jordi ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
STOJKOVIC, Violeta ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Pool assistant - biologie clinique
ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Insuffisance cardiaque - Transplantation
SEIDEL, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur d'appui à la recherche clinique et biostatistique
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Language :
English
Title :
Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Wu AH, Wians F, Jaffe A, Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results Am Heart J 2013 165 995 9 10.1016/j.ahj.2013.02.029 23708172 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000319439900023&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Dumic J, Dabelic S, Flögel M, Galectin-3: an open-ended story Biochim Biophys Acta-Gen Subj 2006 1760 616 35 10.1016/j.bbagen.2005.12.020
Gruson D, Ko G, Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem 2012 45 719 26 10.1016/j.clinbiochem.2012.04.009 22546645 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000305919400004&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, The fibrosis marker galectin-3 and outcome in the general population J Intern Med 2012 272 55 64 22026577 10.1111/j.1365-2796.2011.02476.x http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000305510600006&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F, Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure Arch Cardiovasc Dis 2013 106 541 6 10.1016/j.acvd.2013.06.054 24090952 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000327003000008&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Gupta A, Ghimire G, Hage FG, Guidelines in review: 2013 ACCF/AHA Guideline for the Management of Heart Failure J Nucl Cardiol 2014 21 397 9 10.1007/s12350-013-9832-x 24343106
Hättasch R, Spethmann S, de Boer RA, Ruifrok WP, Schattke S, Wagner M, Galectin-3 increase in endurance athletes Eur J Prev Cardiol 2014 21 1192 9 10.1177/2047487313492069 23723328
Trivax JE, Franklin BA, Goldstein JA, Chinnaiyan KM, Gallagher MJ, DeJong AT, Acute cardiac effects of marathon running J Appl Physiol 2010 108 1148 53 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000277301000019&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 20150567 10.1152/japplphysiol.01151.2009
Peñafiel J, Lupón J, Zamora E, Urrutia A, Vila J, de Antonio M, Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification J Am Coll Cardiol 2013 63 158 66 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000329839200010&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 24076531
Miñana G, Núñez J, Bayés-Genís A, Revuelta-López E, Ríos-Navarro C, Núñez E, ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: a cardiac magnetic resonance study Int J Cardiol 2018 270 336 42 29954670 10.1016/j.ijcard.2018.06.073 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000444609000077&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Bayes-Genis A, Zhang Y, Ky B, ST2 and patient prognosis in chronic heart failure Am J Cardiol 2015 115 64B 9 10.1016/j.amjcard.2015.01.043 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000352253200011&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 25665758
Bayes-Genis A, De Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J Am Coll Cardiol 2014 63 158 66 24076531 10.1016/j.jacc.2013.07.087
Benjamin Dieplinger TM, Soluble ST2 in heart failure Heart Fail Clin 2018 14 41 8 10.1016/j.hfc.2017.08.005 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000415597900005&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 29153199
Lavie CJ, Lee DC, Sui X, Arena R, O'Keefe JH, Church TS, Effects of running on chronic diseases and cardiovascular and all-cause mortality Mayo Clin Proc 2015 90 1541 52 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000365048500014&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 26362561 10.1016/j.mayocp.2015.08.001
Le Goff C, Laurent T, Kaux J-F, Chapelle J-P, Intense physical exercise related to the emergent generation of cardio-vascular risk markers: a review Biol Sport 2012 29 11 6 10.5604/20831862.979290
Knechtle B, Nikolaidis PT, Physiology and pathophysiology in ultra-marathon running Front Physiol 2018 9 634 29910741 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000433898100001&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.3389/fphys.2018.00634
Perk J, De Backer G, Gohlke H, Graham I, Reiner Å.V., Verschuren M, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 2012 33 1635 701 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000306143000024&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1093/eurheartj/ehs092 22555213
Baker P, Davies SL, Larkin J, Moult D, Benton S, Roberts A, Changes to the cardiac biomarkers of non-elite athletes completing the 2009 London Marathon Emerg Med J 2014 31 374 9 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000334673800006&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 23513235 10.1136/emermed-2012-201465
Salvagno GL, Schena F, Gelati M, Danese E, Cervellin G, Guidi GC, The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon Clin Chem Lab Med 2014 52 267 72 24088611 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000329212900019&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Van de Schoor FR, Aengevaeren VL, Hopman MT, Oxborugh DL, George KP, Thompson PD, LJMU research online J Appl Sport Psychol 2015 27 216 34
Legaz-Arrese A, George K, Carranza-García LE, Munguía-Izquierdo D, Moros-García T, Serrano-Ostáriz E, The impact of exercise intensity on the release of cardiac biomarkers in marathon runners Eur J Appl Physiol 2011 111 2961 7 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000297174800008&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1007/s00421-011-1922-3 21442162
Legaz-Arrese A, López-Laval I, George K, Puente-Lanzarote JJ, Mayolas-Pi C, Serrano-Ostáriz E, Impact of an endurance training program on exercise-induced cardiac biomarker release Am J Physiol Circ Physiol 2015 308 H913 20 10.1152/ajpheart.00914.2014
Fallon KE, Sivyer G, Sivyer K, Dare A, The biochemistry of runners in a 1600 km ultramarathon Br J Sports Med 1999 33 264 9 10.1136/bjsm.33.4.264
Siegel AJ, Silverman LM, Holman BL, Elevated creatine kinase MB isoenzyme levels in marathon runners. Normal myocardial scintigrams suggest noncardiac source J Am Med Assoc 1981 246 2049 51 10.1001/jama.1981.03320180041027
Siegel AJ, Januzzi J, Sluss P, Lee-Lewandrowski E, Wood M, Shirey T, Cardiac biomarkers, electrolytes, and other analytes in collapsed marathon runners Am J Clin Pathol 2008 129 948 51 10.1309/4L0M60MGAQBCHMV7 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000255959700014&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 18480012
Meijers WC, van der Velde AR, de Boer RA, ST2 and Galectin-3: ready for prime time? eJIFCC 2016 27 238 52 27683537
Spethmann S, de Boer RA, Hättasch R, Knebel F, Schimke I, Borges AC, Galectin-3 increase in endurance athletes Eur J Prev Cardiol 2013 21 1192 9 23723328
Salvagno GL, Schena F, Gelati M, Danese E, Cervellin G, Guidi GC, The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon Clin Chem Lab Med 2014 52 267 72 24088611 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000329212900019&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices J Hear Lung Transplant 2008 27 589 96 10.1016/j.healun.2008.02.018
Le Goff C, Kaux J-F, Goffaux SB, Cavalier E, Cardiac biomarkers and cycling race J Sport Sci Med 2015 14 475 6
Le Goff C, Lennartz L, Vranken L, Kaux J-F, Cavalier E, Comparison of cardiac biomarker dynamics in marathon, semi-marathon and untrained runners: what is the impact on results interpretation? J Lab Precis Med 2019 4 6 10.21037/jlpm.2019.01.04
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.